Posted by Michael Wonder on 08 Nov 2022
Immunomic Therapeutics receives FDA fast track designation for ITI-3000, a pDNA vaccine, in development for the treatment of Merkel cell carcinoma
8 November 2022 - Immunomic Therapeutics today announced that the US FDA has granted fast track designation to the ITI-3000 program for the treatment of patients with Merkel cell carcinoma.
The company is currently enrolling a Phase I study evaluating ITI-3000, a plasmid DNA vaccine targeting patients with Merkel cell carcinoma.
